Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-336918
Filing Date
2026-08-06
Accepted
2026-08-06 08:45:41
Documents
74
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ck0001991792-20260630.htm   iXBRL 10-Q 1958299
2 EX-10.2 ck0001991792-ex10_2.htm EX-10.2 84108
3 EX-31.1 ck0001991792-ex31_1.htm EX-31.1 17271
4 EX-31.2 ck0001991792-ex31_2.htm EX-31.2 17065
5 EX-32.1 ck0001991792-ex32_1.htm EX-32.1 11062
6 EX-32.2 ck0001991792-ex32_2.htm EX-32.2 11146
  Complete submission text file 0001193125-26-336918.txt   8941303

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ck0001991792-20260630.xsd EX-101.SCH 1367374
78 EXTRACTED XBRL INSTANCE DOCUMENT ck0001991792-20260630_htm.xml XML 1513858
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1640 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1640 DALLAS TX 75247 (949) 409-3700
CG Oncology, Inc. (Filer) CIK: 0001991792 (see all company filings)

EIN.: 371611499 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41925 | Film No.: 261246400
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)